

REMARKS

Claims 1-12 are pending in the present application.

The rejection of Claims 1 and 3 under 35 U.S.C. §102(b) over Scherer et al is obviated by amendment.

The claims as amended relate to a method of improving insulin resistance (Claim 1) and a method of treating type-2 diabetes (Claim 3) by administering an effective amount of a specifically defined composition. Applicants submit that Scherer et al fails to disclose administration of such a composition to achieve the claimed effect.

Therefore, withdrawal of this ground of rejection is requested.

The rejection of Claims 1 and 3 over Claims 1-13 of co-pending application No. 10/514,715 is obviated by amendment. U.S. 10/514,715 claims a drug and method for preventing or treating arteriosclerosis wherein the drug contains C-terminal globular domain of adiponectin, adiponecting, or a gene encoding the domain or adiponectin. In contrast, the present invention relates to a method of improving insulin resistance (Claim 1) and a method of treating type-2 diabetes (Claim 3) by administering an effective amount of a specifically defined composition. Thus, the claims of U.S. 10/514,715 and the present application are distinct and this ground of rejection should be withdrawn.

Acknowledgment that this ground of rejection has been withdrawn is requested.

Applicants submit that the present application is in condition for allowance. Early notification to this effect is respectfully requested.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. Oblon



Vincent K. Shier, Ph.D.
Registration No. 50,552

Customer Number

22850

Tel: (703) 413-3000
Fax: (703) 413-2220
(OSMMN 08/03)